Craig Knott

Principal Health Data Analyst

Craig is an epidemiologist by training and has spent more than a decade analysing a range of retrospective population-based datasets.

He started his career at University College London, where he studied the relationship between different dynamics of alcohol consumption and the risk of non-communicable disease, before moving on to the University of Cambridge where he developed natural experimental studies designed to explore the impact of public policy on human behaviour.

Most recently he has moved into pharmacoepidemiology, working with HDI to establish a series of real-world standing cohorts alongside international partners. Here, cancer registration data are linked to myriad healthcare datasets to explore real-world clinical practice, analyse patient survival, and monitor changes in the therapeutic landscape.

Education and Awards:

University College London, 2013-16
– PhD Epidemiology and Public Health

University College London, 2010-13
– MSc Social Epidemiology

Open University, 2004-09
– BSc Social Sciences with Social Policy

Publications:

Mahmoudpour SH, Knott CS, Amin A, Boutmy E, Verpillat P. Integration of Immuno-oncology (IO) Treatments into Routine Clinical Practice for the Treatment of Patients with Advanced or Metastatic Cancers: Analysis of the England National Cancer Registry. ICPE 2023; 2023, 23-27 Aug.

Chouaid C, Bosquet L, Girard N, Kron A, Scheffler M, et al. An Adjusted Treatment Comparison Comparing Amivantimab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Interion Mutations. Adv Ther. 2023;40(3):1187-1203.

Mistry K, Levell NJ, Hollestein, Wakkee M, Hijsten T, Knott CS, et al. Trends in incidence, treatment and survival of Merkel cell carcinoma epidemiology in England 2004-2018. Br J Dermatol. 2023;188(2):228-236.

Heffernan K, Sen Nikitas FS, Shukla U, Camejo HS, Knott CS. Previously treated recurrent or advanced endometrial cancer in England: a real-world observational analysis. Gynecol Oncol. 2022; 166(2):317-325.

Kidney Cancer UK Accord. Kidney Cancer UK Quality Performance Audit of Kidney Cancer Services in England. Cambridge, UK; 2022.

Ovarian Cancer Audit Feasibility Pilot Steering Group. Short-term mortality in ovarian, fallopian tube ad primary peritoneal carcinomas across England. NHS Digital, Leeds; 2022.

Knott CS, Heffernan K, Nikitas FS, Shukla U, Starkie-Camejo H. 812P Demographics and survival outcomes in patients with advanced or recurrent endometrial cancer (EC) following platinum-based doublet (PBD) in the English real-world (RW) setting. Ann Oncol. 2021; 32(5):S766-S767.

Elsada A, Zalin-Miller A, Knott CS, Caravotas L. A registry study of relapsed or refractory multiple myeloma pre-exposed to 3 or more therapies including a proteasome inhibitor, an immunomodulatory agent and cd38-targeted monoclonal antibody therapy in England. eJHaem 2021:1-5.

Sundar SS, Knott CS, Paley L, et al. Significant variation in treatment and survival outcomes in stage 2–4 ovarian cancer in England: results from the national Ovarian Cancer Feasibility Audit Pilot. Int J Gynecol Canc 2020; 30:A133-A134.

Davies FJ. Knott CS, Kerr C, Adedokun L, Lockhat DM. Utilising Public Health England Datasets to Establish a Standing Cohort of Patients with Metastatic Bladder Cancer: Initial Results and Algorithm Defining Disease Progression. Value Health. 2020; 23(2):S480-S481.

Ovarian Cancer Audit Feasibility Pilot Steering Group. Geographic variation in ovarian, fallopian tube and primary peritoneal cancer treatment in England. Public Health England, London; November 2020.

Knott CS, Panter J, Foley L, Ogilvie D. Changes in the mode of travel to work and the severity of depressive symptoms: a longitudinal analysis of UK Biobank. Prev Med. 2018; 112:61-69.

Knott CS, Britton A, Bell S. Trajectories of alcohol consumption prior to the diagnosis of type 2 diabetes: a longitudinal case-cohort study. Int J Epidemiol. 2018; 47(3):953-965

Further information:

Linkedin profile